ArticleCancer cell2019
A Positive Step toward Understanding Double-Negative Metastatic Prostate Cancer.
Article in Cancer cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Deciphering double-negative prostate cancer: from aggressive subtype to novel therapeutic paradigms.Cell communication and signaling : CCS · 2026Review
- Article
- Ubiquitin C-terminal hydrolase L1 is a regulator of tumor growth and metastasis in double-negative prostate cancer.American journal of clinical and experimental urology · 2024Article
- Phagocytosis-initiated tumor hybrid cells acquire a c-Myc-mediated quasi-polarization state for immunoevasion and distant dissemination.Nature communications · 2023Article
- Molecular Similarities and Differences between Canine Prostate Cancer and Human Prostate Cancer Variants.Biomedicines · 2023Review
- IL-1β expression driven by androgen receptor absence or inactivation promotes prostate cancer bone metastasis.Cancer research communications · 2022Article
- Cancer stem cells: advances in biology and clinical translation-a Keystone Symposia report.Annals of the New York Academy of Sciences · 2021Review
- Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment.Biomedicines · 2021Review
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
Abstract
In this issue of Cancer Cell, Su et al. demonstrate that epigenetic reprogramming by Polycomb Repressive Complex 1 (PRC1) promotes an inflammatory tumor microenvironment in a subtype of metastatic prostate cancer, and show that a PRC1 inhibitor can synergize with immune checkpoint inhibitors to suppress metastasis in mouse models.
Indexed as
Identifiers
31408617What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.